A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus

Journal of Infectious Diseases

Volumn 211, Issue 2, 2015, Pages 216-225

  Schuster, Jennifer E ^a   Cox, Reagan G ^b,f   Hastings, Andrew K ^b   Boyd, Kelli L ^b   Wadia, Jay ^c   Chen, Zhifeng ^d   Burton, Dennis R ^d   Williamson, R Anthony ^e   Williams, John V ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Crucell Vaccine Institute   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e Vaccine Institute   (United Kingdom)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

DBA 2 mouse.; human metapneumovirus; monoclonal antibody; paramyxovirus; respiratory syncytial virus

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 54G10; PALIVIZUMAB; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; BINDING AFFINITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; FEMALE; HUMAN METAPNEUMOVIRUS; HUMAN METAPNEUMOVIRUS INFECTION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LIMIT OF DETECTION; MOUSE; NONHUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEQUENCE ANALYSIS; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; ANIMAL; BAGG ALBINO MOUSE; CHEMOPROPHYLAXIS; DBA MOUSE; DISEASE MODEL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; METAPNEUMOVIRUS; PARAMYXOVIRIDAE INFECTIONS; PROCEDURES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SERODIAGNOSIS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOTHERAPY; METAPNEUMOVIRUS; MICE, INBRED BALB C; MICE, INBRED DBA; NEUTRALIZATION TESTS; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; TREATMENT OUTCOME;

EID: 84922569328     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu307     Document Type: Conference Paper

References (50)

1. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004; 350:443-50
2. Van Den Hoogen BG, De Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7:719-24
3. Edwards KM, Zhu Y, Griffin MR, et al. Burden of human metapneumovirus infection in young children. N Engl J Med 2013; 368: 633-43
4. Englund JA, Boeckh M, Kuypers J, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 2006; 144:344-9
5. Shahda S, Carlos WG, Kiel PJ, Khan BA, Hage CA. The human metapneumovirus: a case series and review of the literature. Transpl Infect Dis 2011; 13:324-8
6. Williams JV, Wang CK, Yang CF, et al. The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis 2006; 193:387-95
7. Agapov E, Sumino KC, Gaudreault-Keener M, Storch GA, Holtzman MJ. Genetic variability of human metapneumovirus infection: evidence of a shift in viral genotype without a change in illness. J Infect Dis 2006; 193:396-403
8. Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis 2003; 187:785-90
9. Van Den Hoogen BG, Herfst S, De Graaf M, et al. Experimental infection of macaques with human metapneumovirus induces transient protective immunity. J Gen Virol 2007; 88:1251-9
10. Erickson JJ, Gilchuk P, Hastings AK, et al. Viral acute lower respiratory infections impair CD8+ T cells through PD-1. J Clin Invest 2012; 122:2967-82
11. Lamb RA, Jardetzky TS. Structural basis of viral invasion: lessons from paramyxovirus F. Curr Opin Struct Biol 2007; 17:427-36
12. Cseke G, Wright DW, Tollefson SJ, Johnson JE, Crowe JE Jr., Williams JV. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol 2007; 81:698-707
13. Herfst S, De Graaf M, Schrauwen EJ, et al. Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains. J Gen Virol 2007; 88:2702-9
14. Peret TC, Boivin G, Li Y, et al. Characterization of human metapneumoviruses isolated from patients in North America. J Infect Dis 2002; 185:1660-3
15. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-7
16. Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010; 125:e35-51
17. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:1932-9
18. Den Broeder A, Van De Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-Tumor necrosis factor-Alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002; 29:2288-98
19. Ulbrandt ND, Ji H, Patel NK, et al. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol 2006; 80:7799-806
20. Williams JV, Chen Z, Cseke G, et al. A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo. J Virol 2007; 81:8315-24
21. Hamelin ME, Gagnon C, Prince GA, et al. Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. Antiviral Res 2010; 88:31-7
22. McLellan JS, Chen M, Chang JS, et al. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol 2010; 84:12236-44
23. Williams JV, Tollefson SJ, Johnson JE, Crowe JE Jr. The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity. J Virol 2005; 79:10944-51
24. Cox RG, Livesay SB, Johnson M, Ohi MD, Williams JV. The human metapneumovirus fusion protein mediates entry via an interaction with RGD-binding integrins. J Virol 2012; 86:12148-60
25. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. J Med Virol 1988; 26:153-62
26. Wen X, Krause JC, Leser GP, et al. Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site. Nat Struct Mol Biol 2012; 19:461-3
27. Hamelin ME, Yim K, Kuhn KH, et al. Pathogenesis of human metapneumovirus lung infection in BALB/c mice and cotton rats. J Virol 2005; 79:8894-903
28. Wyde PR, Chetty SN, Jewell AM, Schoonover SL, Piedra PA. Development of a cotton rat-human metapneumovirus (hMPV) model for identifying and evaluating potential hMPV antivirals and vaccines. Antiviral Res 2005; 66:57-66
29. Skiadopoulos MH, Biacchesi S, Buchholz UJ, et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 2004; 78:6927-37
30. MacPhail M, Schickli JH, Tang RS, et al. Identification of small-Animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design. J Gen Virol 2004; 85:1655-63
31. Kuiken T, Van Den Hoogen BG, Van Riel DA, et al. Experimental human metapneumovirus infection of cynomolgus macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract. Am J Pathol 2004; 164:1893-900
32. Vargas SO, Kozakewich HP, Perez-Atayde AR, McAdam AJ. Pathology of human metapneumovirus infection: insights into the pathogenesis of a newly identified respiratory virus. Pediatr Dev Pathol 2004; 7:478-86; discussion 21
33. Papenburg J, Hamelin ME, Ouhoummane N, et al. Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. J Infect Dis 2012; 206:178-89
34. Vicente D, Montes M, Cilla G, Perez-Yarza EG, Perez-Trallero E. Differences in clinical severity between genotype A and genotype B human metapneumovirus infection in children. Clin Infect Dis 2006; 42: e111-3
35. Mejias A, Chavez-Bueno S, Rios AM, et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 2004; 48:1811-22
36. Mejias A, Chavez-Bueno S, Rios AM, et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 2005; 49:4700-7
37. Crowe JE Jr., Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995; 13:847-55
38. Crowe JE Jr., Firestone CY, Murphy BR. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 2001; 167:3910-8
39. Ulbrandt ND, Ji H, Patel NK, et al. Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus. J Gen Virol 2008; 89:3113-8
40. Yang CF, Wang CK, Tollefson SJ, et al. Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years. Virol J 2009; 6:138
41. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 1998; 177:467-9
42. Kwakkenbos MJ, Diehl SA, Yasuda E, et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 2010; 16:123-8
43. Van Den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA. Analysis of the genomic sequence of a human metapneumovirus. Virology 2002; 295:119-32
44. Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003; 60:51-9
45. Corti D, Bianchi S, Vanzetta F, et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 2013; 501:439-43
46. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 2011; 85: 7788-96
47. De Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007; 45:1019-24.
48. Feltes TF, Sondheimer HM, Tulloh RM, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011; 70:186-91.
49. Kanekiyo M, Wei CJ, Yassine HM, et al. Self-Assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013; 499:102-6.
50. McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342:592-8.